Agios Pharmaceuticals, Inc. AGIO
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- +14.62%
- 1 year
- -22.25%
- Market cap
- 1.86B
- Revenue (ttm)
- 98.34M
- EPS (ttm)
- -7.31
- Shares out
- 59.70M
- Forward P/E
- -7.73
- YTD return
- +14.62%
- 1-year return
- -22.25%
- Volume
- 684.86K
- Avg volume
- 1.09M
- Open
- 30.20
- Previous close
- 29.95
- Day's range
- 30.06 – 31.63
- 52-week range
- 22.24 – 46.00
- Beta
- 0.62
- Analysts
- Buy
- Price target
- 45.88 (+47.0%)
- Earnings date
- Nov 5, 2026
1m +1.13 (+3.76%)
Key statistics
- Enterprise value
- 1.20B
- PEG ratio
- 0.00
- Price / sales
- 18.94
- Price / book
- 1.81
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 259.30%
- Free cash flow
- -274.60M
- Total cash
- 617.58M
- Total debt
- 31.17M
- Return on equity
- -34.34%
- Short % of float
- 11.67%
- 50-day average
- 33.56
- 200-day average
- 31.71
Analyst view
Consensus: buy
- Target (low)
- 32.00
- Target (mean)
- 45.88
- Target (high)
- 72.00
- Strong buy0
- Buy7
- Hold3
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -1.23.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -1.24 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | -1.65 | -1.69 | -0.04 | -2.42% |
| Apr 29, 2026 | Mar 31, 2026 | -1.81 | -1.69 | +0.12 | +6.63% |
| Feb 12, 2026 | Dec 31, 2025 | -1.97 | -1.85 | +0.12 | +6.09% |
| Oct 30, 2025 | Sep 30, 2025 | -1.93 | -1.78 | +0.15 | +7.77% |
| Jul 31, 2025 | Jun 30, 2025 | -1.74 | -1.93 | -0.19 | -10.92% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 7, 2026 | Truist Securities | main | Buy | Buy |
| Sep 21, 2026 | B of A Securities | main | Buy | Buy |
| Aug 7, 2026 | JP Morgan | main | Neutral | Neutral |
| Jul 31, 2026 | Citigroup | main | Buy | Buy |
| Jul 31, 2026 | Truist Securities | main | Buy | Buy |
| Jul 30, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- agios.com
News
Agios: News On Sickle Cell Approval Decision Delay May Not Derail Bull Thesis (Upgrade) 
Agios Pharmaceuticals Says FDA Extends Mitapivat PDUFA Date For Sickle Cell Disease To February 1, 2027 
Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA 
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release 
HC Wainwright & Co. Assumes Agios Pharmaceuticals at Buy, Announces Price Target of $55 
Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $37
Your note
Sign in to keep a note on AGIO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAMS CATHERINE OWEN | Director | Conversion of Exercise of derivative security | Jun 17, 2026 | 10,865 |
| BACKSTROM JAY T | Director | Stock Award(Grant) | Jul 7, 2026 | 1,447 |
| BALLAL RAHUL D. | Director | Conversion of Exercise of derivative security | Jun 17, 2026 | 15,230 |
| CAPELLO JEFFREY D | Director | Conversion of Exercise of derivative security | Jun 17, 2026 | 10,865 |
| FOSTER-CHEEK KAYE I | Director | Conversion of Exercise of derivative security | Jun 17, 2026 | 12,484 |
| FOUSE JACQUALYN A. | Director | Conversion of Exercise of derivative security | Jun 17, 2026 | 154,156 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 10.81% | 6,455,997 | 201.43M | Jun 29, 2026 |
| Farallon Capital Management LLC | 9.91% | 5,917,400 | 184.62M | Jun 29, 2026 |
| State Street Corporation | 5.92% | 3,533,633 | 110.25M | Jun 29, 2026 |
| Lynx1 Capital Management Lp | 5.71% | 3,408,937 | 106.36M | Jun 29, 2026 |
| Shaw D.E. & Co., Inc. | 5.20% | 3,107,005 | 96.94M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.85% | 2,898,197 | 90.42M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.16% | 1,889,447 | 58.95M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.85% | 1,703,564 | 53.15M | Sep 29, 2026 |
| Delaware Group Equity Funds V-Nomura Small Cap Core Fund | 2.84% | 1,695,533 | 52.90M | Aug 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.56% | 1,528,264 | 47.68M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.28% | 1,362,732 | 42.52M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.32% | 788,655 | 24.61M | Jun 29, 2026 |